ZA201302639B - Antibodies for the treatment of hiv - Google Patents

Antibodies for the treatment of hiv

Info

Publication number
ZA201302639B
ZA201302639B ZA2013/02639A ZA201302639A ZA201302639B ZA 201302639 B ZA201302639 B ZA 201302639B ZA 2013/02639 A ZA2013/02639 A ZA 2013/02639A ZA 201302639 A ZA201302639 A ZA 201302639A ZA 201302639 B ZA201302639 B ZA 201302639B
Authority
ZA
South Africa
Prior art keywords
hiv
antibodies
treatment
Prior art date
Application number
ZA2013/02639A
Other languages
English (en)
Inventor
Christine Klinguer-Hamour
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/913,300 external-priority patent/US9090686B2/en
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of ZA201302639B publication Critical patent/ZA201302639B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA2013/02639A 2010-10-27 2013-04-12 Antibodies for the treatment of hiv ZA201302639B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/913,300 US9090686B2 (en) 2009-04-29 2010-10-27 Antibodies for the treatment of HIV
PCT/EP2011/068905 WO2012055980A1 (en) 2010-10-27 2011-10-27 Antibodies for the treatment of hiv

Publications (1)

Publication Number Publication Date
ZA201302639B true ZA201302639B (en) 2013-11-27

Family

ID=44913256

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/02639A ZA201302639B (en) 2010-10-27 2013-04-12 Antibodies for the treatment of hiv

Country Status (10)

Country Link
EP (1) EP2632953A1 (ko)
JP (1) JP2014504147A (ko)
KR (1) KR20140009174A (ko)
CN (1) CN103180342A (ko)
AU (1) AU2011322508A1 (ko)
CA (1) CA2814908A1 (ko)
MX (1) MX2013004710A (ko)
RU (1) RU2013122770A (ko)
WO (1) WO2012055980A1 (ko)
ZA (1) ZA201302639B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014224049B2 (en) * 2013-02-28 2018-11-29 Therabiol, Inc. HIV antigens and antibodies
EP3077417A1 (en) * 2013-12-08 2016-10-12 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
MX2010012435A (es) * 2008-05-14 2011-05-03 Lilly Co Eli Anticuerpos anti-cxcr4.
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
JP2012158521A (ja) * 2009-04-17 2012-08-23 Kureha Corp 外用剤
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
WO2012055980A1 (en) 2012-05-03
EP2632953A1 (en) 2013-09-04
CN103180342A (zh) 2013-06-26
KR20140009174A (ko) 2014-01-22
CA2814908A1 (en) 2012-05-03
MX2013004710A (es) 2013-08-29
RU2013122770A (ru) 2014-12-10
AU2011322508A1 (en) 2013-05-02
JP2014504147A (ja) 2014-02-20

Similar Documents

Publication Publication Date Title
HRP20181320T1 (hr) Ljudska anti-tau protutijela
HK1197400A1 (zh) 治療 的化合物
ZA201403795B (en) Formulations for the treatment of diabetes
EP2736528A4 (en) COMPOSITIONS AND METHODS OF TREATING HIV
EP2618843A4 (en) NEW ANTIBODIES WITH EXCESSIVE HIV-1 NEUTRALIZATION
EP2552874A4 (en) PROCESS FOR PREPARING HEXAFLUOR-2 BUTENE
ZA201103820B (en) Process for the preparation of tenofovir
HK1165813A1 (en) Anti cxcr4 antibodies for the treatment of hiv hiv cxcr4
EP2558432A4 (en) METHOD FOR THE PRODUCTION OF TETRAFLUOROLEFINES
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
ZA201300776B (en) Improved process for the preparation of febuxostat
ZA201207397B (en) Process for the preparation of dexlansoprazole
IL221184A (en) A process for preparing 1-alkylated tetrazole 5 is produced
EP2536436A4 (en) ANTIMIR-451 FOR THE TREATMENT OF POLYCYTHEMICS
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
ZA201302639B (en) Antibodies for the treatment of hiv
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
ZA201306342B (en) The treatment of viral infections
ZA201300083B (en) New drug combinations for the treatment of malaria
PL2593423T3 (pl) Proces wytwarzania środków kontrastowych
PT2390246T (pt) Processo para a preparação de aminaftona
PT2702045T (pt) Método inovador para a preparação de etravirina
EP2558121A4 (en) EPHA3 ANTIBODY FOR THE TREATMENT OF MULTIPLE MYELOMES
PL2598504T3 (pl) Sposób otrzymywania dimiracetamu